Success Stories: Chinese Postdoctoral Researcher Secures NIW Approval After RFE for Groundbreaking Cancer Genomics Research

Client’s Testimonial:

“Thank you for your detailed response and guidance.”

On August 21^st, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Postdoctoral Researcher in the field of Biomedical Science (Approval Notice).

General Field: Biomedical Science

Position at the Time of Filing: Postdoctoral Researcher

Country of Origin: China

State of Residence at the Time of Filing: California

Approval Notice Date: August 21^st, 2025

Processing Time: 1 year, 8 months, 7 days

Case Summary:

We are pleased to share the success story of an EB-2 NIW (National Interest Waiver) approval. This approval was granted to a postdoctoral researcher from China whose research is helping advance bioinformatics-driven cancer treatment. At the time of filing, the client was employed in the United States and had already made important contributions to the field of biomedical science, particularly through her work on cancer genomics, transcription regulation, and multi-omics data analysis.

Research with Substantial Merit and National Importance

The client’s proposed endeavor focuses on building bioinformatics tools to uncover mechanisms driving cancer development and progression. Her work aims to improve therapeutic strategies and inform precision medicine approaches. This research holds national relevance, addressing the urgent need to reduce the burden of cancer and enhance drug discovery efforts.

By integrating single-cell analysis, transcriptomics, and machine learning, her work supports progress in both the healthcare and biotechnology sectors. It also aligns with the U.S. government’s strategic priorities in cancer research and advanced data technologies.

Well Positioned to Advance the Proposed Endeavor

The client holds a Ph.D. in oncology and has developed a strong academic record in cancer genomics and bioinformatics. She has authored 15 peer-reviewed journal articles, including one first-authored and four co-first-authored publications, as well as two abstracts. Her research has been cited over 540 times and published in top journals such as Nature Communications, Molecular Cell, Science Advances, and Gastroenterology. At least nine of her articles rank among the most highly cited in the field of Molecular Biology and Genetics for their publication years.

Her influence is also reflected in peer recognition. She has completed over 20 formal peer reviews for respected scientific journals, affirming her status as an expert evaluator in her discipline. In addition, her work has been supported by national research programs and cited by independent researchers in cancer genetics, tumor immunology, and transcriptional regulation.

NIW Approval and Outlook

The I-140 NIW petition was filed on December 14, 2023. An RFE was issued on April 28, 2025, and the case was approved on August 21, 2025. The RFE response was supported by strong evidence of scholarly achievement, publication impact, citation percentiles, and national relevance.

With NAILG’s support, the client successfully obtained NIW approval and is now well-positioned to continue her research in the United States. Her ongoing contributions to cancer genomics and biomedical data science promise to accelerate breakthroughs in cancer diagnostics and therapies that will benefit public health and national innovation.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.